OverviewSuggest Edit
Zai Lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. The Company's vision is to address the largest unmet medical needs and transform patients’ lives around the world. Zai Lab takes a unique approach to combine both in-licensed products and internal R&D to achieve a rich pipeline.
| Type | Public | |
| Founded | 2013 | |
| HQ | CN | Map |
| Website | zailaboratory.com |
Recent NewsAll News
- MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
- Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
- Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
- Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
Key People/Management at ZAI Lab
Samantha Du
Founder, Chair and Chief Executive Officer
Yongjiang Hei
Chief Medical Officer, Oncology
Harald Reinhart
Chief Medical Officer, Autoimmune and Infectious Diseases
F. Ty Edmondson
Chief Legal Officer
William Liang
Chief Commercial Officer, President, Greater China
Alan Sandler
President, Head of Global Development, Oncology
ZAI Lab Office Locations
ZAI Lab has offices in Suzhou Shi, Cambridge and Menlo Park
Suzhou Shi, CN
218 Xinghu St, Wuzhong Qu
Cambridge, MA, US
245 Main St 2nd floor
Menlo Park, CA, US
1440 O'Brien Dr ste a & c
ZAI Lab Financials and Metrics
ZAI Lab Revenue
| USD | |
|---|---|
Net income (FY, 2016) | (37.5m) |
EBIT (FY, 2016) | (38.5m) |
Market capitalization (14-Jul-2021) | 16.5b |
Closing stock price (14-Jul-2021) | 174.0 |
Cash (31-Dec-2016) | 83.9m |
ZAI Lab's current market capitalization is $16.5 b.
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
General and administrative expense | 2.8m | 6.4m |
R&D expense | 13.6m | 32.1m |
Operating expense total | 13.6m | 32.1m |
EBIT | (16.3m) | (38.5m) |
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 13.2m | 83.9m |
Total Assets | 13.9m | 88.9m |
Current Liabilities | 3.9m | 5.2m |
Non-Current Liabilities | 62.0k | 778.0k |
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash From Operating Activities | (11.5m) | (32.2m) |
Cash From Investing Activities | (738.0k) | (2.7m) |
Cash From Financing Activities | 18.3m | 106.2m |
Net Change in Cash | 6.0m | 70.8m |
- Source: SEC Filings
| USD | FY, 2015 |
|---|---|
Financial Leverage | -0.8 x |
ZAI Lab Cybersecurity Score
ZAI Lab Environment, Social & Governance (ESG) Ratings
ZAI Lab Online and Social Media Presence
ZAI Lab's Trends
ZAI Lab News and Updates
June 16, 2021
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9…
June 16, 2021
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monocl…
June 01, 2021
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the...
June 01, 2021
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
SAN DIEGO, SHANGHAI and SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies hav…
May 28, 2021
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being con…
May 25, 2021
Zai Lab Announces Upcoming Presentations in June Investor Conferences
SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in J…
ZAI Lab Frequently Asked Questions
When was ZAI Lab founded?
ZAI Lab was founded in 2013.
Who are ZAI Lab key executives?
ZAI Lab's key executives are Samantha Du, Yongjiang Hei and Harald Reinhart.
How many employees does ZAI Lab have?
ZAI Lab has 1,194 employees.
Who are ZAI Lab competitors?
Competitors of ZAI Lab include EMS Pharma, Livzon Pharmaceutical Group and Cipla.
Where are ZAI Lab offices?
ZAI Lab has offices in Suzhou Shi, Cambridge and Menlo Park.
How many offices does ZAI Lab have?
ZAI Lab has 6 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies